Nucleus will soon launch a crowdfunding campaign whose goal is to expand the interactions individuals have with the psychedelics industry. The objective of the psychedelics venture studio, which operates as an Iter Investments subsidiary, is to drive psychedelic-assisted therapy forward in the middle of the current global mental health crisis.
Iter Investments’ active portfolio is comprised of more than 15 companies with special access to new investments, including clinics such as Wesana Health and Awakn Life Sciences; active psychedelic ingredient suppliers, including Psygen; drug research and development companies such as Beckley Psytech, Psilera, Clairvoyant, Apex Labs, Reset Pharma, Wesana, Freedom Bio and Awakn Life Sciences; and technology and other supporting infrastructure such as Fluence, aNUma and Tripp.
Dustin Robinson, founder of Iter Investments, stated that the company invested into and launched Nucleus because the fund recognized that the budding psychedelic industry had various gaps that needed to be filled to help it progress.
Nucleus CEO Logan Lenz stated that it was important to the company that those who were interested in owning a stake in the psychedelic-assisted therapy space be afforded the opportunity to do so. This crowdfunding campaign will distribute equity in Nucleus for parties that take part in it.
With regard to this new campaign, Lenz stated that the company believed that providing the opportunity for any party to make an investment into Nucleus through crowdfunding was the best way to allow its audience to own a stake in the company and share in all of its success.
So, why should you take this crowdfunding opportunity?
Nucleus is driven by its mission, which is to offer opportunities and tools to industry stakeholders, including professionals, practitioners and patients as well as investors. The company intends to do so through its proprietary assets portfolio, which currently holds 12 brands. More brands are expected to join in the near term.
The venture studio built these ventures to bridge the technology, data and media gaps in the industry. Content on its platform ranges from offering industry investment insights through Psychedelic Invest and providing updated data and the possibility to connect with professionals in the ecosystem via Neuly to offering a marketing space for mental health practitioners through Psyrise, a directory of practitioners through Psychedelic Finder and a psychedelics-assisted therapy course offering through Matter Academy.
Presently, Nucleus’ community is made up of more than 50,000 members. The company’s new equity crowdfunding campaigns, which invite investors to join, will be open as of Oct. 26, 2022.
As this crowdfunding effort gathers steam, the number of psychedelics startups such as Seelos Therapeutics Inc. (NASDAQ: SEEL) will grow as the years go by.
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.